Abstract
In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.
Original language | English (US) |
---|---|
Pages (from-to) | 151-160 |
Number of pages | 10 |
Journal | Current Breast Cancer Reports |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Sep 24 2015 |
Externally published | Yes |
Keywords
- Assessment
- Biomarkers
- Clinical trials
- Drug development
- Drug efficacy
- Neoadjuvant trials
ASJC Scopus subject areas
- Oncology